Skip to main content
Erschienen in: Fluids and Barriers of the CNS 1/2012

Open Access 01.12.2012 | Short paper

Usefulness of antibody index assessment in cerebrospinal fluid from patients negative for total-IgG oligoclonal bands

verfasst von: Sven Jarius, Peter Eichhorn, Brigitte Wildemann, Manfred Wick

Erschienen in: Fluids and Barriers of the CNS | Ausgabe 1/2012

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Background

Testing for cerebrospinal fluid (CSF)-restricted oligoclonal bands (OCB) by isoelectric focusing is used to detect intrathecally produced total IgG. By contrast, antibody indices (AI) are assessed to test for intrathecally produced antigen-specific IgG. A number of previous cases reports have suggested that AI testing might be more sensitive than OCB testing in detecting intrathecal IgG synthesis.

Findings

Here we report on 21 patients with positive AI for either herpes simplex virus, varicella zoster virus, cytomegalovirus, measles virus, rubella virus, or Borrelia burgdorferi in the absence of total-IgG OCB and, accordingly, in the presence of a normal total-IgG CSF/serum ratio.

Conclusion

Our findings indicate that AI testing should not generally be omitted in OCB-negative patients and provide a rationale for systematic and prospective studies on the comparative sensitivity and specificity of AI and total-IgG OCB testing in infectious and other diseases of the CNS.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​2045-8118-9-14) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

S.J. conceived the study, analysed the data, and wrote the initial draft; P.E. and M.W. conducted and interpreted the laboratory tests; S.J., P.E., B.W., and M.E. revised the manuscript for important intellectual content. All authors have read and approved the final version of the manuscript.
Abkürzungen
AI
antibody index
Bb
Borrelia burgdorferi
CSF
cerebrospinal fluid
CMV
cytomegalovirus
CNS
central nervous system
HSV
herpes simplex virus
IgG
immunoglobulin G
LP
lumbar puncture
MRZR
measles virus, rubella virus, and varicella zoster virus reaction
MS
multiple sclerosis
MV
measles virus
NB
neuroborreliosis
OCB
oligoclonal IgG bands
PCR
polymerase chain reaction
PNS
paraneoplastic neurological syndromes
Q
ratio
RV
rubella virus
VZV
varicella zoster virus
WCC
white cell count.

Introduction

Testing for cerebrospinal fluid (CSF)-restricted total IgG oligoclonal bands (OCB) by isoelectric focusing is a highly sensitive method for detecting intrathecal IgG synthesis, but does not take into account antibody specificity. By contrast, antibody indices (AI) are assessed to test for antigen-specific intrathecal IgG synthesis [1]. It is unclear whether AI assessment is useful in OCB negative patients. Currently, clinicians often do not test for virus- or bacterium-specific AIs on cost grounds if evidence for intrathecal total IgG synthesis as detected by OCB testing is missing.
Back in 1992, however, Felgenhauer and Reiber reported a positive varicella zoster virus (VZV)-specific AI in 6 total-IgG OCB-negative patients with VZV ganglionitis as well as in 4 total-IgG OCB-negative patients with VZV meningitis, suggesting that AI calculation might be more sensitive than total-IgG OCB testing [2]. Here, we report on 21 total-IgG OCB-negative patients with positive AI results for either herpes simplex virus (HSV), VZV, cytomegalovirus (CMV), measles virus (MV), rubella virus (RV), or Borrelia burgdorferi (Bb), thereby providing independent and corroborative evidence for Felgenhauer and Reiber’s hypothesis (see Table1 for details).
Table 1
Patient data and antibody indices to six viral antigens in CSF samples negative for total-IgG oligoclonal bands
No.
Age
Sex
OCBs
AI Bb
AI HSV
AI VZV
AI CMV
AI MV
AI RV
CSF WCC
Suspected diagnosis and indicated by the sender
#1A
32
M
NEG/NEG
Not det.
0.72
0.74
Not det.
0.69
0.77
1557
CSF PCR positive HSV encephalitis
#1B
32
M
NEG/NEG
Not det.
43.40
1.24
Not det.
ND
ND
1456
CSF PCR positive HSV encephalitis, follow-up 19 days later
#1C
32
M
NEG/NEG
ND
53.40
16.30 #
ND
ND
ND
152
CSF PCR positive HSV encephalitis, follow-up a further 3 days later
#2A
33
M
NEG/NEG
Not det.
2.02
1.54
ND
ND
0.83
No data
Blistering rash V2, peripheral facialis paresis
#2B
33
M
NEG/NEG
ND
1.94
1.39
ND
ND
ND
19
Blistering rash V2, peripheral facialis paresis, follow-up 8 days later
#3
30
M
NEG/NEG
ND
2.43
1.12
ND
0.85
1.10
2
No data available
#4
29
F
NEG/NEG
Not det.
2.12
0.99
1.30
ND
0.94
3
No data available
#5A
34
F
NEG/NEG
Not det.
ND
ND
ND
ND
ND
No data
VZV meningoencephalitis
#5B
34
F
NEG/NEG
ND
Not det.
3.99
Not det.
ND
ND
360
VZV meningoencephalitis, follow-up 5 days later
#6
60
F
NEG/NEG
Not det.
1.20
2.40
0.86
ND
ND
2
“FK506-associated leukoencephalopathy”, grand mal
#7
51
M
NEG/NEG
1.26
1.11
2.42
1.03
0.90
1.03
1
“Fatigue and apathy”
#8
42
M
NEG/NEG
Not det.
1.31
3.26
ND
1.03
1.32
3
“Possible multiple sclerosis“
#9
74
F
NEG/NEG
ND
1.43
2.30
Not det.
ND
0.81
2
No data available
#10
50
F
NEG/NEG
ND
Not det.
2.00
ND
0.85
0.67
No data
No data available
#11
71
F
POS/POS*
20.90
1.45
1.32
Not det.
0.97
0.91
4
Neuroborreliosis, encephalitis
#12A
34
F
NEG/NEG
2.60
0.91
0.80
Not det.
0.70
0.80
82
Neuroborreliosis with abducens and facial nerve paresis
#12B
34
F
NEG/NEG
1.70
0.91
0.95
Not det.
1.15
0.83
277
Confirmatory follow-up sample obtained 5 days later
#13
44
M
NEG/NEG
10.60
0.90
1.00
0.88
1.5
ND
No data
"Aseptic Meningitis”
#14
84
M
NEG/NEG
5.31
1.02
0.99
0.85
1.02
1.04
2
No data available
#15
34
F
NEG/NEG
4.79
Not det.
0.99
Not det.
0.92
ND
1
No data available
#16
57
M
NEG/NEG
3.30
0.96
0.88
1.20
0.76
0.75
1
No data available
#17
21
M
NEG/NEG
2.50
Not det.
0.85
Not det.
ND
0.85
1
No data available
#18
38
F
NEG/NEG
ND
1.67
1.00
2.40
0.44
0.94
No data
“Encephalitis”
#19
40
F
NEG/NEG
Not det.
Not det.
16.20
1.43
0.72
0.90
No data
No data available
#20
25
F
NEG/NEG
Not det.
0.92
1.00
Not det.
ND
2.10
1
“Clinically possible multiple sclerosis (Poser)”
#21
60
M
NEG/NEG
ND
0.85
0.87
Not det.
2.80
0.92
No data
No data available
AI = antibody index; Bb = Borrelia burgdorferi; CMV = cytomegalovirus; HSV = herpes simplex virus; MV = measles virus; NEG/NEG = negative in CSF/negative in serum; not det. = not detectable; ND = not done; OCBs = oligoclonal bands; RV = rubella virus; VZV = varicella zoster virus. * Mirror pattern (so-called “pattern 4” according to an international consensus on OCB diagnostics) in the absence of CSF-restricted IgG bands. # Cross-reactivity between HSV and VZV as a result of epitope spreading (see reference [2]).

Methods and results

Testing for OCB was performed by a CSF laboratory with long-standing expertise in the field that takes part in the official German external quality assessment organized by INSTAND e.V. twice a year. OCB were determined by isoelectric focusing followed by anti-IgG immunofixation (Sebia, Fulda, Germany). Serum and CSF levels of antibodies to HSV, VZV, CMV, MV, RV, and Bb were assessed using commercially available enzyme linked immunosorbent assays (Enzygnost, Siemes Healthcare, Eschborn, Germany). Total-IgG and total albumin concentrations in CSF and serum were determined nephelometrically (BN ProSpec, Dade Behring, Germany). Intrathecal synthesis of IgG to HSV, VZV, CMV, MV, RV, and Bb was determined by calculating the respective antibody indices (AI): AI=QIgG[spec]/QIgG[total], if QIgG[total]<Qlim, and AI=QIgG[spec]/Qlim, if QIgG[total]>Qlim, with QIgG[spec]=IgGspec[CSF]/IgGspec[serum], and QIgG[total]=IgGtotal[CSF]/IgGtotal[serum][1, 3]. The upper reference range of QIgG[total], Qlim, was calculated according to Reiber’s formula [1]. No lumbar puncture or phlebotomy was performed for this study, and no stored CSF or serum samples were used for this study. Instead, all data were retrieved retrospectively by an automated database search and analyzed anonymously. As clinical data were not available from all patients due to anonymization, a very conservative cut-off for AI positivity (2.0 instead of 1.3) was applied to preclude false-positive results. No other inclusion and exclusion criteria than OCB negativity and presence of a positive AI for any of those six viral and bacterial antigens in the same paired CSF/serum sample were applied. A positive AI was present for Bb in 7 cases (2.5-20.9; median, 4.794) for HSV in 4 cases (2.02-43.4; 2.28), for VZV in 7 (2–16.2; 2.42), for CMV in 1 (2.40), for MV in 1 (2.80), and for RV in 1 (2.10). In case #1, HSV encephalitis was confirmed by PCR and a follow-up lumbar puncture (LP) confirmed the positive AI, again in the absence of total-IgG OCB. In a second case with positive HSV-AI and negative total-IgG OCB, herpes simplex blisters in the area innervated by the second branch of the trigeminal nerve were present and the patient developed facial nerve palsy; the result was confirmed in a second CSF/serum samples obtained 8 days later. Confirmation from repeat lumbar puncture was also available in a case of neuroborreliosis (Table1). All of these cases were associated with CSF pleocytosis. Other clinical diagnoses associated with positive viral AIs as provided by the senders included “encephalitis”, “meningitis”, “abducens and facial nerve paresis“, and “clinically possible multiple sclerosis”; one VZV-AI positive patient was treated with tacrolimus (FK506), a potent immunosuppressant, at the time of LP (Table1).
To assess the plausibility of the negative total-IgG OCB results, we analysed each patients’ total-IgG CSF/serum ratio (QIgG). Elevated QIgG in the absence of total-IgG OCB positivity would suggest a false-negative OCB result. However, QIgG was found to be normal in all patients (i.e. QIgG<Qlim) as shown in Figure1.

Discussion

These cases confirm that negative total-IgG OCBs in CSF samples might not always predict the absence of positive virus- or bacterium-specific IgG-AIs in patients with suspected CNS infection. Omitting AI testing in OCB negative patients might thus be a possible diagnostic pitfall. In addition to VZV infection [2], positive AIs have previously also been reported in individual total-IgG OCB-negative patients with autoimmune disorders of the central nervous system including anti-GAD antibody positive stiff person syndrome [4], anti-Ri positive paraneoplastic neurological syndromes (PNS) [5], anti-CV2/CRMP5 positive PNS [6], and anti-Yo positive PNS [3].
Around 2-5 % of patients with MS are negative for OCBs. This subgroup, which is small in relative numbers but not so small in absolute numbers due to the high prevalence of MS, is particularly challenging from a diagnostic point of view. A higher sensitivity of antigen-specific AI calculation compared to total-IgG OCB testing might therefore also be of potential relevance for the laboratory diagnosis of multiple sclerosis (MS), since a majority of patients with MS display a polyspecific humoral antibody response to a broad variety of viral and bacterial antigens as determined by AI calculation, with intrathecal antibodies to MV, RV and VZV as its most common constituents (termed MRZ reaction or MRZR), as demonstrated by Reiber and others [79]. Apart from MS, a positive MRZR reaction has also been reported in rare cases of lupus and CNS involvement [7]. MRZR testing is currently performed by many CSF laboratories in Germany, but, in our experience, is so far almost exclusively done in OCB-positive patients. In line with the hypothesis that tests for antigen-specific IgG synthesis might be more sensitive than total-IgG OCB detection, Stich et al. recently reported on positive AIs for MV, RV, and VZV in 2/17 (12 %) total-IgG OCB-negative patients with MS but in none of 11 controls. Similarly, the authors found MV-, RV-, and VZV-specific bands in 3/17 (18 %) total-IgG OCB-negative patients with MS as detected by affinity blotting using recombinant viral antigens and a highly sensitive chemiluminescence detection technique [8]. This is in accordance with a report by Frederiksen and Sindic (1998), who found CSF-restricted VZV- and mumps-specific bands in total-IgG OCB-negative patients with MS using a similar type of assay [9].
On the other hand, the fact that a subset of patients with MS presents with a monospecific AI elevation rather than the typical polyspecific, oligoclonal reaction, at least at first presentation [10], and that the spectrum of positive AIs can be broader than just MV, RV, and VZV and include (though less frequently) positive AIs for Bb, toxoplasma and other viral and bacterial agents can pose differential diagnostic challenges in some cases. Accordingly, in patients in whom MS is a reasonable differential diagnosis, AIs for at least the three main constituents of the MRZ reaction (MV, RV, and VZV) should be determined (approximate costs in Germany, ~20-30 €/AI determination). Moreover, AI results – as laboratory results in general – must always be interpreted in the context of the patient’s overall clinical and neuroradiological presentation and the patient’s CSF findings such as white cell count and differentiation, CSF/serum total-IgM ratios or total-IgA ratios before a definite diagnosis can be made [1, 11]. Bb-IgM assessment can be useful in patients with suspected acute Bb infection; however, it was negative in 6/6 patients in our study (not determined in one).
The reason for the higher sensitivity of AI detection compared to total-IgG detection in the patients reported here is unknown. Infections are often associated with severe blood-CSF barrier dysfunction; the presence of OCB may become undetectable in those cases because of a relative increase of the blood-derived polyclonal IgG fraction. In such cases OCBs may possibly become positive after normalization of barrier dysfunction. However, high CSF/serum albumin ratios were present only in a subset of our patients (see Figure1). Moreover, the higher sensitivity of antigen-specific OCBs compared to total-IgG OCBs detection as demonstrated in a number of studies [35] argues in favour of additional, so far unidentified factors specific for total-IgG OCB detection rather than OCB detection in general.
Possibly, AIs might become positive earlier than total-IgG OCBs. If so, AI assessment might be particularly useful at disease onset. However, as OCBs remained negative in the few patients with follow-up LPs in our study, our study provides no direct evidence for this hypothesis.
There are some caveats. First, as it is the case with IgG responses in general, there might be a delay in AIs becoming positive as indicated by case 1 in Table1; this patients became positive for HSV only at lumbar punctures (LP) #2 and LP #3. However, similar problems apply to HSV PCR, which is sometimes negative at first LP and becomes positive only with time. Therefore, repeat LP is recommended if the initial LP is negative. Second, an expansion of the polyspecific, intrathecal immune response in MS over time has been described [10]. Accordingly, repeat LP might possibly be useful also in individual patients with suspected MS but missing MRZR reaction at first LP. Third, cross-reactivity between VZV and HSV is a well-known phenomenon. However, the true-positive AI generally yields higher values, which usually allows identifying the relevant agent (see patient 1, LP #3). It is therefore recommended to test always for both VZV-AI and HSV-AI. Third, the 21 cases presented here were collected over a period of 9 years, suggesting that the phenomenon is relatively rare; however, it is potentially of high relevance for the individual patient.
In summary, the cases reported here indicate that AI testing should not generally be omitted in total-IgG OCB-negative patients and provides a rationale for systematic and prospective studies on the comparative sensitivity and specificity of AI and total-IgG OCB testing in infectious diseases of the CNS as well as in other indications.

Acknowledgements

This work was supported by research grants from Bayer Healthcare and MerckSerono to BW. We are grateful to D. Menzel, R. Herbst, M. Hoehne, and H. Pahl, Department of Clinical Chemistry, Ludwig Maximilian University, Munich, Germany, for excellent technical assistance.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

S.J. conceived the study, analysed the data, and wrote the initial draft; P.E. and M.W. conducted and interpreted the laboratory tests; S.J., P.E., B.W., and M.E. revised the manuscript for important intellectual content. All authors have read and approved the final version of the manuscript.
Anhänge

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.
Literatur
1.
Zurück zum Zitat Reiber H: Cerebrospinal fluid–physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler. 1998, 4: 99-107.PubMedCrossRef Reiber H: Cerebrospinal fluid–physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler. 1998, 4: 99-107.PubMedCrossRef
2.
Zurück zum Zitat Felgenhauer K, Reiber H: The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system. Clin Investig. 1992, 70: 28-37. 10.1007/BF00422934.PubMedCrossRef Felgenhauer K, Reiber H: The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system. Clin Investig. 1992, 70: 28-37. 10.1007/BF00422934.PubMedCrossRef
3.
Zurück zum Zitat Stich O, Graus F, Rasiah C, Rauer S: Qualitative evidence of anti-Yo-specific intrathecal antibody synthesis in patients with paraneoplastic cerebellar degeneration. J Neuroimmunol. 2003, 141: 165-169. 10.1016/S0165-5728(03)00257-1.PubMedCrossRef Stich O, Graus F, Rasiah C, Rauer S: Qualitative evidence of anti-Yo-specific intrathecal antibody synthesis in patients with paraneoplastic cerebellar degeneration. J Neuroimmunol. 2003, 141: 165-169. 10.1016/S0165-5728(03)00257-1.PubMedCrossRef
4.
Zurück zum Zitat Jarius S, Stich O, Speck J, Rasiah C, Wildemann B, Meinck HM, Rauer S: Qualitative and quantitative evidence of anti-glutamic acid decarboxylase-specific intrathecal antibody synthesis in patients with stiff person syndrome. J Neuroimmunol. 2010, 229: 219-224. 10.1016/j.jneuroim.2010.07.019.PubMedCrossRef Jarius S, Stich O, Speck J, Rasiah C, Wildemann B, Meinck HM, Rauer S: Qualitative and quantitative evidence of anti-glutamic acid decarboxylase-specific intrathecal antibody synthesis in patients with stiff person syndrome. J Neuroimmunol. 2010, 229: 219-224. 10.1016/j.jneuroim.2010.07.019.PubMedCrossRef
5.
Zurück zum Zitat Jarius S, Stich O, Rasiah C, Voltz R, Rauer S: Qualitative evidence of Ri specific IgG-synthesis in the cerebrospinal fluid from patients with paraneoplastic neurological syndromes. J Neurol Sci. 2008, 268: 65-68. 10.1016/j.jns.2007.11.002.PubMedCrossRef Jarius S, Stich O, Rasiah C, Voltz R, Rauer S: Qualitative evidence of Ri specific IgG-synthesis in the cerebrospinal fluid from patients with paraneoplastic neurological syndromes. J Neurol Sci. 2008, 268: 65-68. 10.1016/j.jns.2007.11.002.PubMedCrossRef
6.
Zurück zum Zitat Stich O, Rauer S: Antigen-specific oligoclonal bands in cerebrospinal fluid and serum from patients with anti-amphiphysin- and anti-CV2/CRMP5 associated paraneoplastic neurological syndromes. Eur J Neurol. 2007, 14: 650-653. 10.1111/j.1468-1331.2007.01802.x.PubMedCrossRef Stich O, Rauer S: Antigen-specific oligoclonal bands in cerebrospinal fluid and serum from patients with anti-amphiphysin- and anti-CV2/CRMP5 associated paraneoplastic neurological syndromes. Eur J Neurol. 2007, 14: 650-653. 10.1111/j.1468-1331.2007.01802.x.PubMedCrossRef
7.
Zurück zum Zitat Graef IT, Henze T, Reiber H: Polyspecific immune reaction in the central nervous system in autoimmune diseases with CNS involvement. Z Arztl Fortbild (Jena). 1994, 88: 587-591. Graef IT, Henze T, Reiber H: Polyspecific immune reaction in the central nervous system in autoimmune diseases with CNS involvement. Z Arztl Fortbild (Jena). 1994, 88: 587-591.
8.
Zurück zum Zitat Stich O, Kluge J, Speck J, Rauer S: Detection of virus-specific (measles, rubella, zoster) oligoclonal IgG-bands in CSF from multiple sclerosis patients without oligoclonal bands of total IgG. Mult Scler. 2009, 15: S86-CrossRef Stich O, Kluge J, Speck J, Rauer S: Detection of virus-specific (measles, rubella, zoster) oligoclonal IgG-bands in CSF from multiple sclerosis patients without oligoclonal bands of total IgG. Mult Scler. 2009, 15: S86-CrossRef
9.
Zurück zum Zitat Frederiksen JL, Sindic CJ: Intrathecal synthesis of virus-specific oligoclonal IgG, and of free kappa and free lambda oligoclonal bands in acute monosymptomatic optic neuritis. Comparison with brain MRI. Mult Scler. 1998, 4: 22-26. Frederiksen JL, Sindic CJ: Intrathecal synthesis of virus-specific oligoclonal IgG, and of free kappa and free lambda oligoclonal bands in acute monosymptomatic optic neuritis. Comparison with brain MRI. Mult Scler. 1998, 4: 22-26.
10.
Zurück zum Zitat Petereit HF, Reske D: Expansion of antibody reactivity in the cerebrospinal fluid of multiple sclerosis patients - follow-up and clinical implications. Cerebrospinal Fluid Res. 2005, 2: 3-10.1186/1743-8454-2-3.PubMedPubMedCentralCrossRef Petereit HF, Reske D: Expansion of antibody reactivity in the cerebrospinal fluid of multiple sclerosis patients - follow-up and clinical implications. Cerebrospinal Fluid Res. 2005, 2: 3-10.1186/1743-8454-2-3.PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Reiber H, Peter JB: Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci. 2001, 184: 101-122. 10.1016/S0022-510X(00)00501-3.PubMedCrossRef Reiber H, Peter JB: Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci. 2001, 184: 101-122. 10.1016/S0022-510X(00)00501-3.PubMedCrossRef
Metadaten
Titel
Usefulness of antibody index assessment in cerebrospinal fluid from patients negative for total-IgG oligoclonal bands
verfasst von
Sven Jarius
Peter Eichhorn
Brigitte Wildemann
Manfred Wick
Publikationsdatum
01.12.2012
Verlag
BioMed Central
Erschienen in
Fluids and Barriers of the CNS / Ausgabe 1/2012
Elektronische ISSN: 2045-8118
DOI
https://doi.org/10.1186/2045-8118-9-14

Weitere Artikel der Ausgabe 1/2012

Fluids and Barriers of the CNS 1/2012 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

03.05.2024 Parkinson-Krankheit Nachrichten

Kann eine frühzeitige Stuhltransplantation das Fortschreiten von Parkinson-Symptomen verlangsamen? Die Ergebnisse einer randomisierten Phase-2-Studie scheinen dafür zu sprechen.

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

02.05.2024 Hirnblutung Nachrichten

Erhalten Personen mit einer spontanen Hirnblutung innerhalb von zwei Stunden nach Symptombeginn eine Tranexamsäure-Therapie, kann dies weder die Hämatomexpansion eindämmen noch die Mortalität senken.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.